-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bioventus (NYSE:BVS) Updates FY 2022 Earnings Guidance
Bioventus (NYSE:BVS) Updates FY 2022 Earnings Guidance
Bioventus (NYSE:BVS – Get Rating) issued an update on its FY 2022 earnings guidance on Friday morning. The company provided earnings per share guidance of $0.47-$0.57 for the period, compared to the consensus earnings per share estimate of $0.65. The company issued revenue guidance of $547.50 million-$562.50 million, compared to the consensus revenue estimate of $552.13 million.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley upped their target price on Bioventus from $11.00 to $12.00 and gave the stock an overweight rating in a report on Friday, August 12th.
Get Bioventus alerts:Bioventus Stock Performance
Shares of BVS stock opened at $7.29 on Friday. The company has a market capitalization of $564.62 million, a P/E ratio of -21.76 and a beta of 2.07. The business's 50 day moving average is $7.97 and its two-hundred day moving average is $10.26. The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. Bioventus has a 12-month low of $6.30 and a 12-month high of $17.53.
Bioventus (NYSE:BVS – Get Rating) last issued its quarterly earnings results on Thursday, August 11th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). Bioventus had a positive return on equity of 10.35% and a negative net margin of 4.26%. The business had revenue of $140.33 million for the quarter, compared to analysts' expectations of $140.01 million. During the same quarter in the prior year, the company posted $0.16 EPS. Analysts expect that Bioventus will post 0.54 EPS for the current fiscal year.Hedge Funds Weigh In On Bioventus
A number of hedge funds have recently made changes to their positions in BVS. Jane Street Group LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $355,000. Ergoteles LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $327,000. Rhumbline Advisers increased its holdings in shares of Bioventus by 58.6% in the second quarter. Rhumbline Advisers now owns 44,717 shares of the company's stock valued at $305,000 after purchasing an additional 16,517 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Bioventus by 57.4% in the first quarter. MetLife Investment Management LLC now owns 18,975 shares of the company's stock valued at $268,000 after purchasing an additional 6,917 shares during the last quarter. Finally, Zebra Capital Management LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $254,000. Institutional investors and hedge funds own 44.62% of the company's stock.
About Bioventus
(Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Featured Stories
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
Bioventus (NYSE:BVS – Get Rating) issued an update on its FY 2022 earnings guidance on Friday morning. The company provided earnings per share guidance of $0.47-$0.57 for the period, compared to the consensus earnings per share estimate of $0.65. The company issued revenue guidance of $547.50 million-$562.50 million, compared to the consensus revenue estimate of $552.13 million.
Bioventus(NYSE：BVS-GET Rating)周五上午发布了2022财年最新收益指引。该公司提供的季度每股收益指引为0.47美元至0.57美元，而市场普遍预期的每股收益为0.65美元。该公司发布的收入指引为5.475亿至5.625亿美元，而普遍的收入预期为5.5213亿美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, Morgan Stanley upped their target price on Bioventus from $11.00 to $12.00 and gave the stock an overweight rating in a report on Friday, August 12th.
另外，摩根士丹利在8月12日周五的一份报告中将Bioventus的目标价从11.00美元上调至12.00美元，并给予该股加码评级。
Bioventus Stock Performance
Bioventus股票表现
Shares of BVS stock opened at $7.29 on Friday. The company has a market capitalization of $564.62 million, a P/E ratio of -21.76 and a beta of 2.07. The business's 50 day moving average is $7.97 and its two-hundred day moving average is $10.26. The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. Bioventus has a 12-month low of $6.30 and a 12-month high of $17.53.
上周五，BVS股票开盘报7.29美元。该公司市值为5.462亿美元，市盈率为-21.76，贝塔系数为2.07。该业务的50日移动均线切入位在7.97美元，200日移动均线切入位在10.26美元。该公司的流动比率为1.39，速动比率为1.05，债务权益比率为0.68。Bioventus的12个月低点为6.30美元，12个月高位为17.53美元。
Hedge Funds Weigh In On Bioventus
对冲基金对Bioventus的看法
A number of hedge funds have recently made changes to their positions in BVS. Jane Street Group LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $355,000. Ergoteles LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $327,000. Rhumbline Advisers increased its holdings in shares of Bioventus by 58.6% in the second quarter. Rhumbline Advisers now owns 44,717 shares of the company's stock valued at $305,000 after purchasing an additional 16,517 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Bioventus by 57.4% in the first quarter. MetLife Investment Management LLC now owns 18,975 shares of the company's stock valued at $268,000 after purchasing an additional 6,917 shares during the last quarter. Finally, Zebra Capital Management LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $254,000. Institutional investors and hedge funds own 44.62% of the company's stock.
一些对冲基金最近改变了他们在BVS的头寸。简街集团有限责任公司在第一季度收购了Bioventus的新股份，价值约35.5万美元。Ergoeles LLC在第一季度收购了Bioventus的新股份，价值约327,000美元。Rhumbline Advisers在第二季度增持了Bioventus的股票58.6%。Rhumbline Advisers在上个季度又购买了16,517股后，现在拥有44,717股该公司股票，价值30.5万美元。大都会人寿投资管理有限责任公司第一季度增持了57.4%的Bioventus股票。大都会人寿投资管理有限责任公司现在拥有18,975股该公司的股票，价值268,000美元，在上个季度又购买了6,917股。最后，斑马资本管理有限责任公司在第一季度收购了Bioventus的新股份，价值约为254,000美元。机构投资者和对冲基金持有该公司44.62%的股票。
About Bioventus
关于Bioventus
(Get Rating)
(获取评级)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Bioventus公司是一家医疗设备公司，专注于开发临床治疗方法并将其商业化，这些治疗方法在美国和国际上参与并增强了人体的自然愈合过程。该公司的产品组合包括疼痛治疗，其中包括非手术关节疼痛注射疗法，以及周围神经刺激产品。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于Bioventus(BVS)的研究报告
- 随着管理层重组，股市能否迅速反弹？
- MarketBeat：回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖，但仍被高估吗？
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
收到《Bioventus Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bioventus和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧